Navigation Links
ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Date:11/1/2007

ill be able to move this drug candidate into the clinic later this year, given its great therapeutic potential, not only in cancer, but also in severe eye diseases that are the major causes of blindness."

Svein Mathisen, CEO of BioInvent, added: "The data presented in this seminal paper more fully explains the tumour inhibition findings obtained in our preclinical program to date. Through this experimental work, the development path for the collaboration partners has been clarified and the potential for TB-403, as a novel treatment for cancer, has been emphasized. I feel confident in my belief that TB-403 will secure a prominent place in the oncology armoury."

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in 2008, and TB-403 (Anti-PlGF), which is expected to proceed to Phase I clinical trials by the end of 2007. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

About BioInvent

BioInvent International AB, listed on The Nordic Exchange (OMXS:BINV), is a research-based pharmaceutical company
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle, WARF announce partnership to lure stem cell companies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... BOSTON , June 30, 2015  Juniper ... company focused on developing therapeutics that address unmet ... CFO George Elston will present at ... , Wednesday, July 8, 2015Time: , 4:45 PM ... NYWebcast (live & archive): , www.juniperpharma.com, under  ...
(Date:6/30/2015)... ... June 30, 2015 , ... The maximum number of shares ... outstanding common shares (including shares of unvested restricted stock). On June 29, 2015, the ... price of Cryo-Cell’s shares reported on the OTCBB was $2.29 per share. , The ...
(Date:6/30/2015)... -- The Dr. Samadi Prostate Cancer Center in New ... of new genetic testing methods for men with an elevated ... Dr. Samadi,s Prostate Cancer Center ... risk and optimizing the diagnosis of prostate cancer, both pre-biopsy ... offer these revolutionary genetic tests to men with an elevated ...
(Date:6/29/2015)... Pharnext SAS today announced that data related to its ... Type 1A (CMT1A), is being presented in four posters and ... Biennial Meeting at the Quebec Congress Center in ... 2015. At Poster Viewing Session 4, four posters ... EDT: Poster 23: "A Meta-Analysis Of Randomized ...
Breaking Biology Technology:Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2
... Colo., Aug. 1, 2011 /PRNewswire-iReach/ -- ... a collaboration agreement with SomaLogic, Inc. Under the ... to SomaLogic,s proprietary proteomic assays for an undisclosed ... together to plan two clinical research studies in ...
... YORK, Aug. 1, 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, ... "AOBO"), a pharmaceutical company dedicated to improving health through ... of prescription and over the counter ("OTC") products, today ... financial results on Tuesday, August 9, 2011, after the ...
... MA (July 28, 2011) Researchers have developed a ... populations while leaving others unaffected. Led by ... School, the group focused on serotonin-producing neurons, observing how ... serotonin neurons are turned down. While their findings affirm ...
Cached Biology Technology:WAVi Co. Announces Collaborative Agreement with SomaLogic, Inc. 2American Oriental Bioengineering to Announce Second Quarter 2011 Financial Results on August 9, 2011 2Researchers target, switch off serotonin-producing neurons in mice 2Researchers target, switch off serotonin-producing neurons in mice 3
(Date:6/16/2015)... QUEBEC CITY , June 16, 2015 /CNW ... announce their partnership centralized around the incorporation of ... mobile point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented ... the BIO International Conference at the ... from June 15 th to ...
(Date:6/16/2015)... Fingerprint Cards has received an order of 375 ... from one of its module partners in Asia ... the third quarter 2015. The sensors will be used by ... Jörgen Lantto, CEO of FPC, comments: " This order   ... smartphone OEMs in integrating touch fingerprint sensors in   their ...
(Date:6/15/2015)... -- According to a new market research ... and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image ... The Natural Language Processing Market is expected to grow ... the forecast period 2015-2020. Browse 65 ... spread   through 155 P ages and in-depth ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
... scientists at Stanford University is subjecting chunks of rock to ... of curbing climate change. By exposing a ... have obtained critical new data about the large-scale underground storage ... of global warming. "About 60 percent of ...
... cells within the lung as they move around and ... the causes of Idiopathic Pulmonary Fibrosis (IPF) a disease ... , IPF fills the delicate gas exchange region of ... Duke University Medical Center researchers have discovered that some ...
... Open access to information about biodiversity is of crucial ... and climate change research and education. "Non-Commercial" restrictions on ... to addressing these problems, says a review paper published ... . Halting the loss of biodiversity demands that ...
Cached Biology News:AGU meeting: Stanford scientists subject rocks to hellish conditions to combat global warming 2AGU meeting: Stanford scientists subject rocks to hellish conditions to combat global warming 3AGU meeting: Stanford scientists subject rocks to hellish conditions to combat global warming 4New insights come from tracing cells that irreversibly scar lungs 2Creative Commons 'non-commercial' licenses impede the re-use of biodiversity information 2
... to study co-translational and initial post-translational ... as signal peptide cleavage, membrane insertion, ... examined by the translation of the ... presence of these microsomal membranes. In ...
... your strain of cells competent or increase ... unrivalled expertise in producing competent cells. Lucigen’s ... Chemically competent or electrocompetent cells ... Quality control performance testing ...
... products ATP-Free using Mo Bio luciferase assay. Mo ... service that will allow you to certify your ... and enable you to deliver them to your ... ATP detection limit is 3.5 x 10-12 /l, ...
Glucagon-like peptide-1 (GLP-1 (1-36) amide)...
Biology Products: